3-[1-(1-hydroxyhex-6-yl)-4-piperidinyl]-6-fluoro-1, 2-benzisoxazole | 150332-91-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 英文名称: 3-[1-(1-hydroxyhex-6-yl)-4-piperidinyl]-6-fluoro-1, 2-benzisoxazole
• 英文别名: 3-[1-(1-hydroxyhex-6-yl)-4-piperidinyl]-6-fluoro-1,2-benzisoxazole；3-[1-(1-Hydroxyhex-6-yl]-4-piperidinyl]-6-fluoro-1,2-benzisoxazole；6-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]hexan-1-ol
• CAS: 150332-91-5
• 化学式: C₁₈H₂₅FN₂O₂
• 分子量: 320.407
• InChiKey: VQKMCZNVRYZPOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  49.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,4-(甲二氧基)异氰酸苯酯 、 3-[1-(1-hydroxyhex-6-yl)-4-piperidinyl]-6-fluoro-1, 2-benzisoxazole 生成 1-[6-(3,4-Methylenedioxyphenylcarbamoyloxy)hexyl]-4-(6-fluoro-1,2-benzisoxazol-3-yl) piperidine
  参考文献：
  名称：

  Antipsychotic piperidine derivatives

  摘要：

  本发明涉及治疗活性吡啶烷衍生物，具有以下式子1的结构：##STR1## 其中，R.sup.1，R.sup.2，A，X和Y如规范中所定义。这些化合物在治疗与中枢神经系统、心血管系统或胃肠道疾病相关的疾病方面有用。

  公开号：

  US05378714A1
• 作为产物：
  描述：

  6-氯-1-己醇 、 6-氟-3-哌啶-4-基-1,2-苯并异唑盐酸盐 在 lithium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以25.6%的产率得到3-[1-(1-hydroxyhex-6-yl)-4-piperidinyl]-6-fluoro-1, 2-benzisoxazole
  参考文献：
  名称：

  Mesolimbic selective antipsychotic arylcarbamates

  摘要：

  4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidine has been linked to various arylcarbamates to obtain compounds having affinity for dopamine-D-1 and -D-2, serotonin 5HT(2A) and alpha(1)-adrenoceptors. When Linkers with restricted flexibility are used, the biological activity is reduced indicating that a bended conformation is needed in this series of bioactive molecules. Compounds with a relatively low D-2/5HT(2A) affinity ratio in receptor binding experiments and high affinity for the alpha(1)-adrenoceptors exhibit a pharmacological profile which suggests a preferential effect on the mesocorticolimbic dopaminergic system and an 'atypical' antipsychotic activity. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80009-9

文献信息

• Antipsychotic piperidine derivatives
  申请人：Novo Nordisk A/S

  公开号：US05378714A1

  公开（公告）日：1995-01-03

  The present invention relates to therapeutically active piperidine derivatives, of formula 1 ##STR1## wherein, R.sup.1, R.sup.2, A, X and Y are as defined in the specification. The compounds are useful in the treatment of indications related to the CNS-system, cardiovascular system or to gastrointestinal disorders.

  本发明涉及治疗活性吡啶衍生物，化学式为1，其中，R.sup.1、R.sup.2、A、X和Y如规范中定义。这些化合物在治疗与中枢神经系统、心血管系统或胃肠道疾病相关的症状方面具有用途。
• CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE
  申请人：NOVO NORDISK A/S

  公开号：EP0679085A1

  公开（公告）日：1995-11-02
• US5378714A
  申请人：——

  公开号：US5378714A

  公开（公告）日：1995-01-03
• [EN] CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE
  申请人：——

  公开号：WO1993010742A2

  公开（公告）日：1993-06-10

  [EN] The present invention relates to therapeutically active piperidine derivatives, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The compounds are useful in the treatment of indications related to the CNS-system, cardiovascular system or to gastrointestinal disorders.
  [FR] Dérivés thérapeutiquement actifs de pipéridine, leur procédé de préparation, et compositions pharmaceutiques les contenant. Ces composés sont utilisés dans le traitement des troubles du système nerveux central et du système cardio-vasculaire, et des troubles gastro-intestinaux.
• Mesolimbic selective antipsychotic arylcarbamates
  作者：John Bondo Hansen、Anders Fink-Jensen、Birgitte V. Christensen、Frederick C. Grønvald、Lone Jeppesen、John P. Mogensen、Erik B. Nielsen、Mark A. Scheideler、Francis J. White、Xu-Feng Zhang

  DOI：10.1016/s0223-5234(99)80009-9

  日期：1998.11

  4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidine has been linked to various arylcarbamates to obtain compounds having affinity for dopamine-D-1 and -D-2, serotonin 5HT(2A) and alpha(1)-adrenoceptors. When Linkers with restricted flexibility are used, the biological activity is reduced indicating that a bended conformation is needed in this series of bioactive molecules. Compounds with a relatively low D-2/5HT(2A) affinity ratio in receptor binding experiments and high affinity for the alpha(1)-adrenoceptors exhibit a pharmacological profile which suggests a preferential effect on the mesocorticolimbic dopaminergic system and an 'atypical' antipsychotic activity. (C) Elsevier, Paris.